Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
about
Maintaining clarity: Review of maintenance therapy in non-small cell lung cancerMaintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old ideaCost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysisA systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic reviewCost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III studyMaintenance therapy in NSCLC: why? To whom? Which agent?Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes.Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study.Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerEconomic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC).Patient comprehension and attitudes toward maintenance chemotherapy for lung cancerMaintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications.Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer.Metronomics as maintenance treatment in oncology: time for chemo-switch.Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.Maintenance therapy in non-small cell lung cancer.Effectiveness of maintenance treatments for nonsmall cell lung cancer.Antineoplastic Treatment of Advanced-Stage Non-Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011).Maintenance Therapy for NSCLC: Consensus and Controversy.Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
P2860
Q26996389-275EE21F-5F03-4229-90B8-185E45C06133Q27011282-587FE3E9-0479-486A-B545-3F91A5048578Q34112596-73B53120-EF22-47D5-B2B1-B39DA56DC6D9Q34511171-71477E5D-31CE-4A14-93F2-7BEC8B35E6EDQ34566773-806F7086-F423-4373-A7E4-C0651351932EQ34727967-BB60C5C5-1DFD-4C9C-9FF4-1957069500BCQ34742887-F15CADA1-A5F8-4117-947A-9B050FCBE227Q34996046-E61A5C57-DD17-4FE6-A816-749ABCEEC77CQ35041521-EC66E35C-A5BA-48E9-B501-DB3BE2B2F25FQ35106391-54DC2885-9129-4E2F-B000-BF8AEDDEB618Q35146923-648158D6-481D-417F-803F-9E72C65C18A1Q35167535-42336BD5-2BD7-4FB8-B7A6-29EA96B4EB2EQ35397077-064AC356-E04B-43F5-8FBE-99E5111111CFQ35752978-38E00FB4-4AB8-4282-BE6A-D912B8FBAF2DQ36138536-5801C392-14B0-43CE-8E74-BFCB87D39C9CQ36236671-73372A1B-C13C-42D5-BC17-18C17915521CQ37401072-85FEBEBB-C555-450E-8044-27EFA5D03C67Q37566838-AFEB124E-C796-4236-B6F5-0572BEF5AFE2Q37707573-855C3E57-3BA6-4592-87DF-8491F80524B3Q38369105-542569BB-2A51-4879-AF24-5E7F3971AAD6Q38509236-DA75C60E-6E11-4A3E-A1C1-53FBB75A71F0Q38956327-431A42C6-C695-420C-BD55-5BA8310762D4Q39043072-22634461-E881-4023-AA8A-DD47658A3BE1Q41841863-E700F3EA-7D23-4626-82A7-C916FE404F71Q50238133-82983176-527B-44B2-8FAA-414967E4D7A8
P2860
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Cost-effectiveness of pemetrex ...... us non-small cell lung cancer.
@en
Cost-effectiveness of pemetrex ...... us non-small cell lung cancer.
@nl
type
label
Cost-effectiveness of pemetrex ...... us non-small cell lung cancer.
@en
Cost-effectiveness of pemetrex ...... us non-small cell lung cancer.
@nl
prefLabel
Cost-effectiveness of pemetrex ...... us non-small cell lung cancer.
@en
Cost-effectiveness of pemetrex ...... us non-small cell lung cancer.
@nl
P2093
P1476
Cost-effectiveness of pemetrex ...... us non-small cell lung cancer.
@en
P2093
Anthony Lawson
Astra M Liepa
Catherine Muehlenbein
Lee Schwartzberg
Robert Klein
Ron Wielage
Steve Babineaux
P304
P356
10.1097/JTO.0B013E3181E15D16
P577
2010-08-01T00:00:00Z